Zur Kurzanzeige

2018-11-02Zeitschriftenartikel DOI: 10.25646/6040
Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature
dc.contributor.authorBender, Jennifer K.
dc.contributor.authorCattoir, Vincent
dc.contributor.authorHegstad, Kristin
dc.contributor.authorSadowy, Ewa
dc.contributor.authorCoque, Teresa M.
dc.contributor.authorWesth, Henrik
dc.contributor.authorHammerum, Anette M.
dc.contributor.authorSchaffer, Kirsten
dc.contributor.authorBurns, Karen
dc.contributor.authorMurchan, Stephen
dc.contributor.authorNovais, Carla
dc.contributor.authorFreitas, Ana R.
dc.contributor.authorPeixe, Luísa
dc.contributor.authorDel Grosso, Maria
dc.contributor.authorPantosti, Annalisa
dc.contributor.authorWerner, Guido
dc.date.accessioned2019-03-29T11:05:40Z
dc.date.available2019-03-29T11:05:40Z
dc.date.issued2018-11-02none
dc.identifier.other10.1016/j.drup.2018.10.002
dc.identifier.urihttp://edoc.rki.de/176904/6075
dc.description.abstractVancomycin-resistant enterococci (VRE) are important nosocomial pathogens. Invasive VRE infections are difficult to treat since common therapeutic options including ampicillin and glycopeptides often fail. In vitro, most VRE remain susceptible to last-resort antibiotics such as linezolid, tigecycline and daptomycin. However, neither tigecycline nor linezolid act in a bactericidal manner, and daptomycin has proven activity only at high dosages licensed for treating enterococcal endocarditis. Despite these pharmacological and therapeutic limitations, reports on resistance to these last-resort drugs in VRE, and enterococci in general, have increased in recent years. In this review, we briefly recapitulate the current knowledge on the mode of action as well as the known and novel mechanisms of resistance and describe surveillance data on resistance to linezolid, tigecycline and daptomycin in enterococci. In addition, we also suggest a common nomenclature for designating enterococci and VRE with resistances to these important last-resort antibiotics.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectvanAeng
dc.subjectvanBeng
dc.subjectVREeng
dc.subjectLinezolideng
dc.subjectTigecyclineeng
dc.subjectDaptomycineng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleUpdate on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclaturenone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/6075-8
dc.identifier.doihttp://dx.doi.org/10.25646/6040
dc.type.versionpublishedVersionnone
local.edoc.container-titleDrug Resistance Updatesnone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.sciencedirect.com/science/article/pii/S1368764618300487none
local.edoc.container-publisher-nameElseviernone
local.edoc.container-volume40none
local.edoc.container-issueSeptember 2018none
local.edoc.container-reportyear2018none
local.edoc.container-year2018none
local.edoc.container-firstpage25none
local.edoc.container-lastpage39none
local.edoc.rki-departmentInfektionskrankheitennone
dc.description.versionPeer Reviewednone

Zur Kurzanzeige